Alert detail

LCD L38125: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies — Noridian

Policy ID: LCD-L38125Specialty: OncologyAdded: 6/5/2026Effective: March 28, 2024lcd
Routine

What changed

New LCD for myeloid malignancies requires billing team review.

Who’s affected: Oncology billing teams · Effective: March 28, 2024

Affected codes

Primary source: View the official CMS/MAC document ↗

Get the action steps and full analysis

This change affects 9 billing codes.

Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.

Audit documentation

Building an audit file?

The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Oncology audit pack — $349One-time purchase · not a subscription

Not ready to subscribe?

Get the free weekly reimbursement brief for Oncology— the week’s changes and deadlines, delivered to your inbox. No account required.

LCD L38125: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies — Noridian